Capital commitment

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version

Retrieved on: 
Wednesday, March 27, 2024
EUR, Brussels Stock Exchange, Exercise, Atlas, Capital commitment, Capital, Disclosure, Therapy, USD, Subscription business model, Consultant, Security (finance)

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.
  • Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 9,014,821,287 outstanding ordinary shares carrying voting rights (compared to 7,384,386,505 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Retrieved on: 
Tuesday, March 26, 2024
EUR, Brussels Stock Exchange, Exercise, Atlas, Capital commitment, Capital, Disclosure, Therapy, USD, Subscription business model, Consultant, Security (finance)

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.
  • Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 9,014,821,287 outstanding ordinary shares carrying voting rights (compared to 7,384,386,505 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Retrieved on: 
Thursday, March 21, 2024
EUR, Brussels Stock Exchange, Exercise, Atlas, Capital commitment, Capital, Disclosure, Therapy, USD, Subscription business model, Consultant, Security (finance)

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.
  • Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 7,384,386,505 outstanding ordinary shares carrying voting rights (compared to 5,753,951,723 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Retrieved on: 
Monday, March 4, 2024
Therapy, USD, Capital commitment, Subscription business model, Disclosure, Exercise, Consultant, EUR, Brussels Stock Exchange, Atlas, Capital, Security (finance)

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.
  • Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 5,753,951,723 outstanding ordinary shares carrying voting rights (compared to 4,938,734,332 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Retrieved on: 
Friday, January 19, 2024
Subscription business model, Consultant, Atlas, Brussels Stock Exchange, Capital commitment, EUR, USD, Disclosure, Therapy, Capital, Exercise, Security (finance)

Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.
  • Leuven, BELGIUM – January 19, 2024 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 326,086,956 new ordinary shares on January 9, 2024, for a total amount of EUR 150,000, as the result of the conversion of 6 convertible bonds, and the issuance of 217,391,304 new ordinary shares on January 16, 2024, for a total amount of EUR 100,000, as the result of the conversion of 4 convertible bonds, both pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC
    Following completion of capital increases through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 4,032,937,232 outstanding ordinary shares carrying voting rights (compared to 3,489,458,972 outstanding ordinary shares prior to the two aforementioned issuances).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Sunday, November 19, 2023
Disclosure, Agreement, Cayman, USD, Capital commitment, Capital, EUR, Brussels Stock Exchange, Subscription business model, SRS, Atlas, Security (finance), Boston, Limited

Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 3.489.458.972 outstanding ordinary shares carrying voting rights (compared to 3,247,913,079 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Thursday, November 16, 2023
Disclosure, Agreement, Cayman, USD, Capital commitment, Capital, EUR, Brussels Stock Exchange, Subscription business model, SRS, Atlas, Security (finance), Boston, Limited

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 3,247,913,079  outstanding ordinary shares carrying voting rights (compared to 3,112,043,514 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Monday, November 6, 2023
Capital commitment, Cayman, Disclosure, EUR, SRS, USD, Subscription business model, Term Asset-Backed Securities Loan Facility, Brussels Stock Exchange, Agreement, Atlas, Capital, Security (finance), Limited

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 3,112,043,514 outstanding ordinary shares carrying voting rights (compared to 2,956,764,011 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Friday, November 3, 2023
Capital commitment, Cayman, Disclosure, EUR, SRS, USD, Subscription business model, Term Asset-Backed Securities Loan Facility, Brussels Stock Exchange, Agreement, Atlas, Capital, Security (finance), Limited

Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,956,764,011 outstanding ordinary shares carrying voting rights (compared to 2,879,124,260 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Friday, October 20, 2023
Capital commitment, Cayman, Disclosure, EUR, SRS, USD, Subscription business model, Term Asset-Backed Securities Loan Facility, Brussels Stock Exchange, Agreement, Atlas, Capital, Security (finance), Limited

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,879,124,260 outstanding ordinary shares carrying voting rights (compared to 2,758,351,314 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.